Project Grant R25CA291583
- This federal Project Grant award, valued at $682,272.00, was provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program. The award will fund a research project entitled "Assessing Feasibility and Acceptability of a Multifaceted EHR-Integrated Mobile Health Intervention Following Radical Cystectomy" at the University of Michigan. The goal of the project is to develop and evaluate a novel, technology-enabled intervention to reduce...
- The University of Michigan was awarded a $2,284,054 Project Grant by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research (CFDA 93.394) federal grant program. The 4-year grant, which began on September 1, 2025, will support research to transform molecular cancer screening through the development of stimulated Raman histology and deep neural networks. The project aims to improve access to molecular cancer testing by creating innovative diagnostic tools and methods...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $2,820,337.00 to the Regents of the University of Michigan to develop new methods to directly measure metabolic pathway activity in mouse models and patients with glioblastomas (GBMs), which are deadly and incurable brain cancers. The goal is to identify optimal metabolic treatment strategies for GBM patients by evaluating the safety, on-target activity, and potential efficacy of new...
- This $640,135 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a new generation of potent menin inhibitors that can overcome resistance observed in current menin inhibitor treatments for acute myeloid leukemia (AML) patients. The award recipient, the Regents of the University of Michigan, will leverage its expertise in medicinal chemistry and cancer biology to design and test these next-generation menin...
- This $150,104 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to understand the evolutionary trajectories of complex genomic rearrangements in cancer. The project aims to develop novel computational approaches, "AGAVE" and "ROSE", to characterize the timing and dynamics of focal amplifications and structural variants during tumor evolution. The research will map these evolutionary patterns across...
- The Department of Health and Human Services' National Cancer Institute has awarded a $128,199 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to the Regents of the University of Michigan. The grant, titled "Deciphering the Functional Role of PPP2R1A Mutations in Cancer," aims to evaluate the functional impact of mutations in the PPP2R1A gene, which encodes the alpha isoform of the A subunit of the protein phosphatase 2A (PP2A) tumor suppressor....
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $509,246 to the Regents of the University of Michigan to conduct research on early drivers of prostate cancer lineage plasticity. The project aims to identify key transcriptional regulators that repress androgen receptor signaling and promote alternate differentiation programs in prostate cancer, with the goal of preventing lineage plasticity and disease progression. By...
- The National Cancer Institute (NCI) awarded a $159,450 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Wayne State University to support the "NextGen Oncology Scholars: Nurturing Tomorrow's Pioneers" program. This 5-year grant, beginning August 15, 2025 and ending July 31, 2030, aims to cultivate the next generation of cancer researchers by providing undergraduate students with hands-on research experiences, didactic training, clinical exposure, and structured...
- This Project Grant award of $162,305 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to model and characterize the early cellular and molecular changes that occur upon activation of the anaplastic lymphoma kinase (ALK) in lung cancer. The project, led by Dr. Peggy Hsu at the University of Michigan, aims to develop a single cell atlas of ALK+ lung cancer, examine the role of the transcription factor NRF2 in ALK+ lung cancer initiation, and provide a...
- The National Cancer Institute (NCI) awarded a $386,866 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Regents of the University of Michigan to develop individualized estimates of treatment benefit from hormone therapy for men with prostate cancer. The project aims to integrate models for other-cause mortality risk, distant metastases, and prostate cancer-specific mortality to provide personalized estimates of treatment outcomes, and to develop a web...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $319,505 to the Regents of the University of Michigan to build nationwide investigator capacity in methods for adapting and personalizing cancer control interventions. The project aims to address the growing demand for new methodological skills in developing adaptive interventions, which are evidence-based protocols that guide how individual information can be used to deliver personalized cancer control services. The 5-year project, starting on August 1, 2025, will leverage the university's expertise in advanced trial designs such as Sequential Multiple Assignment Randomized Trials (SMARTs) and Micro-Randomized Trials (MRTs) to provide comprehensive training and support the adoption of these methods across the cancer control continuum, including risk reduction, treatment, survivorship, and palliative care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $319.5k | 8/1/25 |